Phase I Study of Carfilzomib for the Treatment of T-Cell Lymphoma

Trial Profile

Phase I Study of Carfilzomib for the Treatment of T-Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Carfilzomib (Primary)
  • Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; T cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 May 2017 Planned End Date changed from 1 Apr 2016 to 1 Apr 2018.
    • 12 Aug 2015 Planned End Date changed from 1 Dec 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov record
    • 12 Aug 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top